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SUMMARY 
Title: Vitamins in health and disease in children  
Author: Nina Sepideh Tighnavard Mollasarai  
 This review will discuss vitamin D, B6 and B12, with focus on their source, metabolic pathway, 
physiology and deficiency. What they have in common is their essential function in normal child 
development, growth and health.  
 Vitamin D deficiency is an increasing public health problem in infants and children worldwide, 
causing rickets and growth failure. Vitamin D deficiency can be of various causes, but the number 
one factor responsible for this increase is most probably insufficient sun exposure and the excessive 
use of sunscreen. Exclusively breastfed infants and infants born to vitamin D deficient mothers are 
at high risk of developing nutritional vitamin D deficiency.  
 Vitamin B6 is essential for normal brain function and development. Unlike vitamin D, 
nutritional vitamin B6 deficiency is rare, due to its availability in various food products. Deficiency 
states are most commonly seen in children with malabsorption diseases, in severe malnutrition due 
to poverty and in inborn errors of vitamin B6 metabolism. Although the inborn errors of metabolism 
are extremely rare one such error will be highlighted here, pyridoxine dependent epilepsy. It is an 
autosomal recessive disease where defective lysine catabolism causes decreased levels of vitamin 
B6 in the brain, resulting in seizures and other neurological manifestations.  
 Vitamin B12 is involved in the metabolism of every cell in the human body, most importantly in 
DNA synthesis. As a consequence, vitamin B12 deficiency mostly affects tissues of high metabolic 
activity, i.e epithelial, nervous and hematopoietic systems. The clinical manifestations of vitamin 
B12 deficiency has a wide spectrum and are usually non specific, thus there is a need for high index 
of suspicion to find the correlation. Vitamin B12 is exclusively found in food of animal origin, 
putting infants of vegan or vegetarian mothers at the highest risk of developing a deficiency. As 
vegan or vegetarian diets are trending, women planning to get pregnant need to be informed about 
the crucial function of vitamin B12 and the need for supplementation during pregnancy and 
lactation.  
 Although some deficiencies are rare and some are common, they are all clinically preventable 
diseases by implementing prevention and screening programs (especially in high risk groups), 
supplementation and food fortification. Early diagnosis and treatment are of utmost importance in 
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all vitamin deficiencies since it prevents devastating irreversible consequences and significantly 
improves outcome in severely deficient children.  
Keywords: vitamin D deficiency, rickets, vitamin B6 deficiency, pyridoxine dependent epilepsy, 
vitamin B12 deficiency, megaloblastic anemia, pernicious anemia.  
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SAŽETAK 
Naslov: Vitamini u zdravlju i bolestima djece 
Autor: Nina Sepideh Tighnavard Mollasarai 
 Ovaj pregled će se osvrnuti na vitamine D, B6 i B12, sa fokusom na njihov izvor, metabolički 
proces, fiziologiju te nedostatak. Ono što imaju zajedničko je njihova esencijalna funkcija u 
normalnom rastu, razvoju i zdravlju djeteta.  
 Nedostatak vitamina D je rastući problem javnog zdravstva kod dojenčadi i djece diljem 
svijeta, uzrokujući rahitis i zastoj u rastu. Nedostatak vitamina D može biti uzrokovan različitim 
čimbenicima, ali je glavni uzrok odgovoran za taj porast najvjerojatnije neadekvatna izloženost 
suncu te pretjerano korištenje krema za sunce. Isključivo dojenčad i novorođenčad čije su majke u 
nedostatku vitamina D su u visokom riziku razvoja prehrambenog nedostatka vitamina D.  
 Vitamin B6 je esencijalan u normalnom razvoju i funkciji mozga. Za razliku od vitamina D, 
nutritivni manjak vitamina B6 je rijedak radi njegovog prisutstva u različitim hranidbenim 
prozivodima. Stadiji nedostatka su najčešće viđeni u djece s bolestima malabsorpcije, u teškoj 
podhranjenosti radi siromaštva te u urođenim greškama metabolizma B6. Makar su urođene greške 
metabolizma rijetke jednu od njih čemo naglasiti ovdje, piridoksin ovisnu epilepsiju. To je 
autosomalna recesivna bolest gdje neispravan katabolizam lizina uzrokuje snižene nivoe vitamina 
B6 u mozgu, te prouzrokuje napdaje i ostale neurološke manifestacije.  
 Vitamin B12 je umiješan u metabolizam svake stanice u ljudskom tijelu, najvažnije u sintezu 
DNK. Kao postljedica, nedostatak vitamina B12 najviše utiče na tkiva visoke metaboličke aktivnosti, 
npr. epitela, živaca i hematopoetskih sustava. Kliničke manifestacije nedostatka vitamina B12 imaju 
širok spektar i obično su nespecifične, dakle postoji potreba za visokim indeksom sumnje kako bi se 
našla korelacija. Vitamin B12 isključivo postoji u hrani životinjskog porijekla, činivši dojenčad 
veganskih ili vegetarijanskih majki najrizičnijom skupinom razvoja nedostatka. Kako su veganski i 
vegetarijanski tipovi prehrane u trendu, žene koje planiraju trudnoću trebaju biti informirane o 
presudnoj funkciji vitamina B12 te potrebom za dopunom tokom trudnoće i dojenja.  
 Makar su neki nedostaci rijetki a neki učestali, to su klinički spriječive bolesti ako se 
implementiraju programi prevencije i probira (pogotovo u visoko rizičnim skupinama), 
suplementacije i fortifikacije hrane. Rana dijagnoza i liječenje su iznimno važni u svim nedostacima 
vitamina jer sprječavaju razarajuće nepovratne posljedice i značajno poboljšavaju ishod u djece sa 
velikim deficitom.  
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Ključne riječi: nedostatak vitamina D, rahitis, nedostatak vitamina B6, piridoksin ovisna epilepsija, 
nedostatak vitamina B12, megaloblastična anemija, pernicijozna anemija. 
"4
1.0 VITAMIN D 
1.1 Source and metabolic pathway   
 Vitamin D is a lipid soluble vitamin existing in different forms in the body. Vitamin D3 
(cholecalciferol) is primarily formed in the skin after exposure to UVR from the sun by conversion 
of its precursor 7-dehydrocholesterol. Less than 10% is obtained from dietary sources (Norris JM 
2001) in the form of either vitamin D2 (ergocalciferol) or vitamin D3. There are very few natural 
dietary sources containing vitamin D, the main ones being margarine, fatty fish, liver and egg yolk 
(Misra M et al. 2008). Vitamin D2 and D3 are of equivalent potency and in order to become active 
require further metabolism in the liver and kidney to 25-hydroxyvitamin D (calcidiol) and 1,25- 
dihydroxyvitamin D (calcitriol), respectively. The former is the storage form of vitamin D whereas 
the latter is the active form delivered to target organs to express its functions (Marcdante KJ, 
Kliegman RM 2015). 
1.2 Physiology   
 Vitamin D plays an essential role in calcium and phosphate homeostasis in the body, mainly by 
promoting their absorption in the intestines and decreasing their excretion by the kidneys. The 
maintenance of adequate concentrations of these minerals enables mineralization of bones. Other 
functions of Vitamin D include suppression of PTH release from the parathyroid gland, regulation 
of osteoblast and osteoclast function and bone resorption (Figure 1).   
 Vitamin D has a wide variety of functions in the body, not just involving bone and mineral 
homeostasis, proven by the presence of its receptor in most organs. Vitamin D is proven to help in 
modulation of cell growth, neuromuscular and immune function, many genes encoding proteins that 
regulate cell proliferation, differentiation and apoptosis and the reduction of inflammation (Gupta R 
et al. 2014). Some studies suggest that it may reduce the risk of autoimmune diseases and protect 
against diabetes and some cancers (Casey CF et al. 2010).  
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1.3 Vitamin D deficiency  
1.3.1 Etiology 
  
 Low levels of vitamin D results in hypocalcemia and hypophosphatemia, which could over 
time lead to rickets in infants and children or osteomalacia in adolescence and adults (Misra M 
2016). Rickets is defined as decreased or defective bone mineralization in growing children. The 
skeletal phenotype is partly due the direct effects of vitamin D deficiency on bone and partly due to  
secondary hyperparathyroidism that develops in the vitamin D deficient state, as PTH causes 
calcium mobilization and bone resorption.  
 To my knowledge there is currently no data to show the exact prevalence of rickets, however  
documentations prove that this problem still exists today (Misra M et al. 2008). Although rickets is 
rare in developed countries since the introduction of fortified food products and infant formulas, the 
frequency has been increasing worldwide. Possible factors accounting for this increase include the 
excessive use of sunscreen and that children are spending more and more time indoors watching TV 
or playing computer games (Lowdon J 2011).  
 Children at risk of developing rickets are usually those who are malnourished, exclusively 
breastfed, not exposed to enough sun or those having chronic illnesses. 
Vitamin D deficiency can be due to various causes; factors interfering with the synthesis of vitamin 
D, decreased nutritional intake, perinatal factors, genetic disorders, malnutrition and various 
medications.  
 The primary source of vitamin D synthesis is exposure to UVR from the sun, which has 
increasingly been limited or blocked by excessive use of sunscreen due to the increased awareness 
of its strong association with the development of skin cancer. The amount of dermal vitamin D 
synthesis depends on several factors, skin pigmentation being the most important. Dermal vitamin 
D synthesis is reduced in dark skinned children due to the blocking action of melanin, hence 
requiring as much as 3 to 10 times more sun exposure as light-skinned children to reach  
recommended concentration. Other factors include age, duration of exposure, amount of skin 
exposed and geographic-related factors. 
 Insufficient intake of vitamin D containing foods or food fortified with vitamin D can cause 
vitamin D deficiency, particularly in breastfed infants. Exclusive breastfeeding doesn't provide 
sufficient vitamin D to fetus since the concentration of vitamin D in breastmilk is too low, even in 
non-deficient mothers. 
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 The only source of vitamin D in the fetus is from the mother across the placenta. During the 
fetal skeletal calcification which occurs in the third trimester, vitamin D from the mother is critical. 
A poor maternal vitamin D status during this period can cause fetal vitamin D deficiency, and in 
severe cases fetal rickets. Premature infants are particularly susceptible (Misra M 2016). 
 Vitamin D malabsorption from the gut is associated with conditions that impair fat absorption, 
since vitamin D is fat soluble and therefor chylomicron dependent. Rickets can be found in children 
with celiac disease (Pazianas M et al. 2005), inflammatory bowel disease, cystic fibrosis and 
cholestasis (Misra M et al. 2008).  
 Inherited diseases that cause vitamin D deficiency are rare and are caused by mutations either 
in genes encoding the enzymes involved in pathway of vitamin d synthesis (1-alpha-hydroxylase 
and 25-hydroxylase) or the vitamin D receptor (VDR).  
 Some medications that also can increase the risk of vitamin D deficiency if taken chronically  
are glucocorticoids, anti-fungals, anticonvulsants and anti-retroviral agents (Lee JY et al. 2013).   
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Figure 1. Vitamin D metabolic pathway. 
1.3.2 Clinical manifestations  
 Vitamin D deficient children may present with a range of symptoms and signs, from none to 
varying degrees of rickets and/or hypocalcemic symptoms, such as seizures, muscle weakness, 
tetany and hypoplasia of the dental enamel. The clinical manifestations of vitamin D deficient 
rickets peaks between 6 and 18 months of life, during the period of rapid growth (Wagner CL, Greer 
FR 2008). The growth plates thickens due to continued normal expansion in the absence of 
adequate mineralization. As a result these children will have the classical signs of widening of the 
wrists and ankles (Gupta R et al. 2014). General softening of the bones is responsible for the knock-
knees (genu valgum) or bowlegs (genu varum) deformity. Other signs include prominence of 
costochondral junctions (rachitic rosary), pigeon chest deformity (pectus carinatum), frontal 
bossing, delayed closure of the fontanelles and craniotabes (Marcdante KJ, Kliegman RM 2015). A 
child with subtile symptoms of irritability, bone pain, delayed motor development such as standing 
and walking, delayed growth, and a history of frequent falling should raise the suspicion of rickets 
(Thacher TD, Clarke BL 2011).  
1.3.3 Diagnostic evaluation 
 The best indicator for vitamin D status is 25-hydroxyvitamin D, due to its long half-life of  2-3 
weeks and its non-susceptibility to changes in PTH concentrations. (Thacher TD, Clarke BL 2011).  
Standards for defining normal and abnormal serum 25-hydroxyvitamin D levels are not well 
established because of inconsistent evidence, especially in the pediatric population (Misra M 2016), 
thus variations are commonly seen. The vitamin D status can be sufficient, insufficient or deficient 
as shown in Table 1.  
 When suspecting a child with vitamin D deficient rickets the medical anamnesis should include 
dietary habits with focus on calcium and vitamin D intake, medication history and history of sun 
Table 1. Vitamin D status based on 25-hydroxyvitamin D levels
Vitamin D status 25-hydroxyvitamin D level (ng/mL)
Sufficiency 
Insufficiency 
Deficiency
20-100 
12-20 
≤12
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exposure. Confirmation is mainly done with laboratory and radiographic findings. In addition to  
25-hydroxyvitamin D levels, serum measurements in the workup should include calcium, 
phosphorous, ALP, PTH, and 1,25-dihydroxyvitamin D levels (Gupta R et al. 2014). These 
measurements are necessary to determine whether the etiology of rickets is due to low calcium 
levels secondary to vitamin D deficiency or due to phosphorus deficiency. Rickets due to 
phosphourous deficiency, so called phosphopenic rickets, will not be covered here.  
 In a vitamin D deficient state, low calcium levels stimulate the parathyroid gland to increase its 
secretion of PTH, which in turn stimulates calcium reabsorption in renal tubules, bone resorption 
and 1-alpha-hydroxylase activity (Misra M et al. 2008). This compensatory increase in PTH 
secretion is responsible for the variations in calcium, phosphorus and 1,25-dihydroxyvitamin D 
levels occurring in early stages of rickets (Table 2). ALP is a product of osteoblasts and is an 
excellent marker for disease activity, indicating a state of increased bone turnover, thus always 
elevated in rickets (Van Straalen JP et al. 1991). 
 The radiographic changes of rickets can best be observed at the growth plate of rapidly 
growing bones. Thus these changes are most prominent at distal ulna and at the metaphyses above 
and below the knees, which may show widening, cupping and fraying (Gupta R et al. 2014). Other 
changes may include osteopenia, cortical thinning of long bones, stress fractures and deformities of 
the shafts as previously mentioned under clinical presentation (Misra M et al. 2008). 
↑: increased; ↓: decreased; N: normal.
1.3.4 Prevention and treatment 
 In order to prevent vitamin D deficiency and rickets in infants and children, a daily intake of at 
least 400 IU is recommended, beginning in the first few days of life (Table 3) (Wagner CL, Greer 
FR 2008). Exclusive breastfeeding of infants does not provide sufficient vitamin D to meet this 
criteria, thus supplementation is recommended. Supplementation should also be given to infants 
ingesting less than 1000 ml of fortified formula per day (Carpenter T 2016). Children at risk and 
those who do not receive enough vitamin D through natural sources, fortified food or sun exposure 
should also be given supplements. Given the fact that sun exposure is the number one source of 
Table 2. Biochemical findings in vitamin D deficient rickets
Calcium Phosphorus ALP 25-OH D 1,25-(OH)2 D PTH
↓/N ↓/N ↑/↑↑ ↓ ↑/N ↑
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vitamin D and its direct association with skin cancer, a balance of the amount of exposure is 
necessary (Misra M et al. 2008). Another way of prevention is through screening for vitamin D 
deficiency, specially in high risk children, i.e those with chronic diseases associated with fat 
malabsorption, dark pigmented children who live at higher latitudes, children on glucocorticoid or 
anticonvulsant therapy and children with elevated ALP levels.  
 Therapy for vitamin D deficiency is indicated in infants and children with clinical 
manifestations of hypocalcemia and/or rickets and with serum vitamin D levels outside normal 
range. The most commonly used treatment consists of either vitamin D2 or vitamin D3, the latter 
being preferred. Table 3 shows the recommended vitamin D dosing scheme for vitamin D deficient 
rickets who do not have any underlying defect in intestinal absorptive function. Treatment should 
also consist of daily calcium supplementation of 30 to 50 mg per kg body weight (Carpenter T 
2016). The dosing for vitamin D deficient children without rickets is debatable, some recommend 
the same dosing scheme as for children with rickets while some suggest lower doses (400 IU/day in 
children < 1 month, and up to 1000 IU/day for older children; Carpenter T 2016).  
IU: International Units; po: per oral; * followed by maintenance dose of 400 IU/day; ** followed by maintenance dose 
of 600 IU/day.  
Table 3. Vitamin D dosing scheme in rickets
Prevention 400 IU/day
Treatment  
Infants < 1 month 
Infants 1-12 months 
Children 1-12 years 
Children ≥ 12 years
1000 IU/day po for 2-3 months* 
1000-2000 IU/day po for 2-3 months* 
2000-6000 IU/day po for 3 months** 
6000 IU/day for 3 months**
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2.0 VITAMIN B6 
2.1 Source and metabolic pathway  
 Vitamin B6 is a water soluble vitamin present in the body in the form of pyridoxine, pyridoxal, 
pyridoxamine, and their respective 5’-phosphate derivatives. The main source of vitamin B6 is from 
the diet, mainly from meat, cereals, various vegetables, fruits, nuts and beans. A small proportion is 
synthesized from intestinal bacterial flora. After intestinal absorption they are transported to the 
liver in order to become phosphorylated by pyridoxal kinase. Pyridoxine phosphate and 
pyridoxamine phosphate become further oxidized by pyridoxine 5’-phosphate oxidase (PNPO) to 
the active coenzyme pyridoxal 5’-phosphate (PLP), which is released into the circulation bound to 
albumin (Surtees R et al. 2006). Since only free vitamin bases can cross the BBB and enter the 
CNS, the PLP-albumin complex is cleaved by a tissue non-specific alkaline phosphatase to free 
pyridoxal (TNSALP). Studies on mice lacking this enzyme has been done, where these mice died 
due to seizures, proving its critical function in transporting vitamin B6 into the brain (Waymire KG 
et al. 1995).  
2.2 Physiology  
 Pyridoxal phosphate acts as a cofactor for many enzymes involved in metabolism of amino 
acids, carbohydrates, lipids and brain neurotransmitters (eg. dopamine, serotonin, glycine, 
glutamate, GABA) as well as the synthesis of neuroprotective compounds (Surtees R et al. 2006). 
Other functions include immune development, steroid hormone modulation and biosynthesis of 
hemoglobin and prostaglandins (Marcdante KJ, Kliegman RM 2015). Thus, deficiency of vitamin 
B6 can have many diverse consequences.   
2.3 Vitamin B6 deficiency 
2.3.1 Etiology 
 Unlike vitamin D, deficiency of vitamin B6 due to insufficient dietary intake is rare, due to its 
presence in a wide variety of foods. Nevertheless, it can be seen in severely malnourished children 
or in children with conditions causing malabsorption, such as IBD and celiac disease.   
Vitamin B6 can be destroyed by cooking and food processing, reducing its availability with up to 50 
"11
percent (Pazirandeh S, Burns DL 2017). This has been shown to cause serious consequences, as an 
outbreak of infants with seizures occurred by the heating of improperly processed formulas 
(Marcdante KJ, Kliegman RM 2015).  
 Medications that can interfere with the function of vitamin B6 are for example isoniazid, 
penicillamine, hydralazine  and cycloserine (Pazirandeh S, Burns DL 2017). 
 There are currently four recognized inborn errors of metabolism affecting brain PLP, all 
causing seizures of varying degrees. PNPO deficiency is the only one known to stem from defective 
vitamin B6 metabolism and transport. Two inborn errors of other metabolic pathways include 
pyridoxine dependent epilepsy (PDE) and hyperprolinemia type II. The last one is TNSALP 
deficiency (hypophosphatasia), an inherited disorder of bone mineralization where affected infants 
sometimes present with seizures (Surtees R et al. 2006). 
2.3.2 Clinical manifestations 
 The classical signs and symptoms of vitamin B6 deficiency in children include microcytic 
anemia, dermatitis-like skin eruptions, glossitis, angular chelitis, immunosuppression, somnolence, 
confusion, irritability and seizures (Frye RE 2016). As mentioned previously PLP is involved in the 
metabolism of neurotransmitters, whereas the inhibitory neurotransmitter GABA is one of them.  
Severe vitamin B6 deficiency can therefore lead to the development of seizures as a consequence of 
decreased GABA concentrations in the brain (Kluger G 2008).  
2.3.3 Diagnostic evaluation  
  
 The diagnosis of vitamin B6 deficiency is usually based on clinical findings and it should 
always be considered in the differential diagnosis of infantile seizures, specially if the seizures are 
unresponsive to anticonvulsant treatment (Johnson LE 2016). Although there is currently no single 
accepted laboratory test in confirming the diagnosis of vitamin B6 deficiency, the serum PLP level 
is the best indicator for vitamin B6 status. Other useful laboratory tests include measurements of 
erythrocyte transaminase activity and urinary excretion of the vitamin B6 degradation product 
pyridoxic acid (Pazirandeh S, Burns DL 2017).  
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2.3.4 Prevention and treatment  
 In order to achieve optimal body vitamin B6 levels in otherwise healthy children, a daily intake 
ranging from 0.1 to 1.3 mg is recommended, depending on the age of the child (Pazirandeh S, 
Burns DL 2017). Preventive measures include dietary adjustments and vitamin B6 supplementation 
in children at risk (i.e with diseases of malabsorption).  
 The previously mentioned inborn metabolic disorders all respond to treatment with high doses 
of  pyridoxine or PLP.   
 
2.3.5 Pyrodoxine dependent epilepsy 
 Pyridoxine dependent epilepsy (PDE) is an extremely rare autosomal recessive disease. The  
exact prevalence is unknown but ranges from approximately 1:20 000 to 1:600 000 births (Stockler 
S et al. 2011). Recently PDE was proven to result from mutations in the ALDH7A1 gene encoding 
for antiquitin, an ADH essential for the catabolism of lysine in the brain (Mills PB et al. 2006). As a 
consequence accumulations of L-pipecolic acid, piperidine-6-carboxylate (P6C) and α-aminoadipic 
semialdehyde (αAASA) occurs (Figure 2). The accumulated P6C inactivates PLP through the 
formation of a P6C-PLP complex, thus decreasing free PLP levels in the brain. As a result GABA 
synthesis decreases, thereby greatly reducing the threshold for seizures.  
 PDE classically presents with seizures during early infancy, refractory to anticonvulsant 
treatment but responsive to high doses of pyridoxine. Although multiple types of seizures are 
reported in these infants, the dramatic presentation of status epileptics is characteristic (Stockler S et 
al. 2011). Other clinical manifestations include irritability, abnormal cry, dystonic movements, 
respiratory distress, abdominal distention, bilious vomiting, hepatomegaly, metabolic acidosis and 
shock (Mills PB et al. 2010). In one third of cases PDE presents in an atypical manner with late-
onset seizures, up to 3 years of age. Other atypical features include prolonged seizure-free interval 
up to 5 years after pyridoxine withdrawal and initial response to conventional anticonvulsant 
therapy (Jagadeesh S et al. 2013) (Stockler S et al. 2011).  
 The diagnosis of PDE is based on clinical and electroencephalographic response to pyridoxine 
treatment in infants not responding to anticonvulsants, followed by lab- and genetic testing. 
Elevated urine or plasma αAASA is a strong indicator for PDE. Plasma P6C and pipecolic acid and 
CSF pipecolic acid may also be elevated (Stockler S et al. 2011). Additional testing includes EEG 
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readings, usually being severely abnormal, and brain imaging with possible atrophic or dysplastic 
changes (Mills PB et al. 2010). Diagnosis is confirmed with mutations in ALDH7A1 gene. 
 In acute treatment, IV administration of a single dose of 50-100 mg pyridoxine usually results 
in cessation of seizures within a few minutes (Jagadeesh S et al. 2013). As IV pyridoxine can cause 
respiratory depression, it should be done in the ICU with close monitoring of vital signs. Seizures 
recur upon pyridoxine withdrawal, consequently requiring lifelong enteral treatment with either 
pyridoxine or PLP 15-30 mg/kg/day (Stockler S et al. 2011). Recently a new therapeutic approach 
consisting of pyridoxine, arginine supplementation and a lysine-restricted diet is shown to be 
superior to mono-therapy with pyridoxine. Although early diagnosis and treatment significantly 
improves the outcome, most children will unfortunately still have developmental delay and 
intellectual disability (Bennet CL 2005).  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Figure 2. Lysine catabolic pathway and its relation to GABA synthesis. 
GAD: glutamate decarboxylase 
3.0 VITAMIN B12 
3.1 Source and metabolic pathway  
 Vitamin B12 (cobalamin, Cbl) is a water soluble vitamin present in the body in the form of 
hydroxocobalamin, methylcobalamin (methyl-Cbl) and adenosylcobalamin (adenosyl-Cbl) (Smith 
J, Coman D 2014). The human body is unable to synthesize cobalamin, hence the only source being 
from dietary products. It’s exclusively found in foods of animal origin such as meat and dairy 
products, thereof the need for supplements in strict vegetarians and vegans. Synthetic vitamin B12 
found in supplements and fortified foods is mainly in the form of cyanocobalamin (cyano-Cbl).  
 The absorption of cobalamin is a complex process, depending on several factors. In the 
presence of gastric acid and pepsinogen secretion cobalamin is released from food proteins. It then 
binds R-binder proteins, only to be released again by the action of pancreatic proteases in the 
duodenum. The ultimate absorption occurs in the distal ileum, a process requiring the intrinsic 
factor (IF), a binding protein secreted from gastric parietal cells. After absorption into the 
enterocytes by the means of specific ileal receptors (cubilin-amnionless), the IF-Cbl complex 
dissociates and free cobalamin is released into the circulation bound to either transcobalamin (TC) 
or haptocorrin (HC), transporting cobalamin to target tissues (Rasmussen SA et al. 2001).  
 Unlike other water soluble vitamins cobalamin is stored in the liver in large concentrations, 
sufficient to last up to several years after cessation of dietary cobalamin intake/absorption. This is 
mainly possible due to the highly efficient enterohepatic circulation after its secretion in the bile 
(Smith J, Coman D 2014). 
3.2 Physiology 
 Cobalamin is involved in the metabolism of every cell in the human body, most importantly in 
DNA synthesis and carbohydrate, lipid and protein metabolic pathways (Marcdante KJ, Kliegman 
RM 2015). Methyl-Cbl and adenosyl-Cbl are essential cofactors for methionine synthase and 
methylmalonyl-CoA mutase, respectively (Figure 3). Methionine synthase is the enzyme catalyzing 
the conversion of homocysteine to methionine, a reaction coupled with demethylation of 
methyltetrahydrofolate (methyl-THF) to tetrahydrofolate (THF). These reactions provide two 
products necessary for DNA synthesis, THF and methionine. Methionine is also a precursor of      
S-adenosylmethionine, the methyl donor in the formation of phosphatidylcholine from 
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phosphatidylethanolamine, both of which are major components of myelin. Apart from being a 
universal methyl group donor in more than 100 reactions in our body, methylmalonyl-CoA mutase 
catalyzes the conversion of methylmalonyl-CoA to succinyl-CoA (Smith J, Coman D 2014). 
Methylmalonyl-CoA is formed in the catabolic pathway of cholesterol, branched chain amino acids 
and odd chain fatty acids and its conversion into Succinyl-CoA is essential in order to enter the 
citric acid (Krebs) cycle to generate ATP. 
3.3 Vitamin B12 deficiency  
3.3.1 Etiology  
 Cobalamin deficiency in children can be due to decreased nutritional intake, various conditions 
of malabsorption or inborn errors affecting metabolism, absorption or transport.   
 The source of fetal cobalamin is from the mother across the placenta, reaching serum levels  
twice those of maternal levels. The excess is stored in the fetal liver, providing cobalamin sufficient 
to last approximately 6-12 months postpartum, without taking into account the cobalamin provided 
through breastmilk. Deficient levels during this period is therefore most likely due to maternal 
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Figure 3. Vitamin B12 cofactor activity. 
deficiency (Incecik F et al. 2010), nowadays commonly caused by the increased trend of vegan or 
vegetarian diets. Other possible maternal causes are poverty and malnutrition, unrecognized 
pernicious anemia, previous gastric bypass surgery or short gut syndrome (Smith J, Coman D 
2014). 
 Inefficient cobalamin absorption from the gut may occur as a consequence of a defect in any of 
the mechanisms required for its normal absorption. Secondary causes of defective cobalamin 
absorption can be dues to gastric or ileal resection, decreased gastric acid secretion, pancreatic 
insufficiency, small bowel bacterial overgrowth, intestinal parasite infections and IBD. Inborn 
errors of cobalamin absorption includes congenital pernicious anemia and Imerslund-Gräsbeck 
disease, with a lack of IF and a defect in the cubilin-amnionless receptor, respectively. Although 
very rare, the classical form of autoimmune pernicious anemia with its onset in adulthood can 
sometimes present in children as juvenile pernicious anemia. It’s important to keep in mind that 
these children can have additional autoimmune diseases, as part of PAS type 1 and 2. 
 Other inborn errors of cobalamin deficiency are transcobalamin deficiency, R-binder 
deficiency as well as defective intracellular metabolism, affecting the synthesis of the coenzymes 
methyl-Cbl and/or adenosyl-Cbl. Methylmalonic aciduria is a classical type of organic acuduria 
where methylmalonic acid cannot be converted to succinyl-CoA, due to a deficiency in 
methylmalonyl-CoA mutase or its cofactor adenosyl-Cbl, resulting in accumulation of high 
quantities of methylmalonic acid in blood. With the exception of R-binder deficiency, all the above 
mentioned inborn errors are thought to be inherited in an autosomal recessive manner (Rasmussen 
SA et al. 2001). 
3.3.2 Clinical manifestations  
 Cobalamin deficiency in newborns and infants usually presents with non specific 
manifestations, such as failure to thrive, vomiting, irritability, weakness, poor feeding and apathy 
(Table 4) (Zengin E et al. 2009). Later on infants may present with the characteristic manifestations 
of cobalamin deficiency; megaloblastic anemia, varying degrees of pancytopenia, hypersegmented 
neutrophils and neurological dysfunction. Older children may have additional findings, such as 
glossitis, depression and personality changes. Abnormal skin pigmentation has also been reported in 
severe cobalamin deficiency (Smith J, Coman D 2014).  
 The delayed DNA synthesis in rapidly dividing RBC precursors in the bone marrow results in 
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ineffective erythropoiesis, producing large and defective erythrocytes with an increase in nucleus to 
cytoplasm ratio.  
 The neurological signs and symptoms include irritability, hypotonia, hyporeflexia, tremor, 
ataxia, seizures, nystagmus, developmental delay, developmental regression, paresthesia and brain 
atrophy (Incecik F et al. 2010). Still little is known about the underlying mechanisms of the 
neurological features associated with cobalamin deficiency, but disruptions in myelination of brain 
and spinal cord is thought to play a major role. As myelination mostly occurs in the first two years 
of life, cobalamin deficiency in children during this period puts them at particular risk of 
neurological impairment. The cause of myelin disruption is thought to involve several mechanisms. 
Firstly, deficiency of adenosyl-CoA leads to accumulation of odd chain fatty acids, which are 
thought to disrupt the myelin. Secondly, deficiency of methyl-CoA results in decreased formation of 
the methyl donor, S-adenosylmethionine, important for myelin synthesis. Lastly     
S-adenosylmethionine is thought to increase production of TNF-α, which also may contribute to 
defective myelination (Smith J, Coman D 2014). 
3.3.3 Diagnostic evaluation 
 As the clinical manifestations of cobalamin deficiency usually are non specific, delays in 
diagnosis is common, thus the need for high index of suspicion (Smith J, Coman D 2014). 
Cobalamin deficiency often coexists with folate (vitamin B9) deficiency, which have a very similar 
presentation clinically as well as serologically, thereof the need for investigation of both vitamins.  
 The initial lab tests should include serum cobalamin and folate levels, CBC and red blood cell 
MCV. Cobalamin values can differ depending on the method used, establishing a normal range is 
therefor difficult. In general, however, the cobalamin levels can be interpreted as normal, borderline 
or low (Table 5). The inborn errors of cobalamin transport and metabolism can have serum 
Table 4. Clinical findings of vitamin B12 deficiency in children
General Neuropsychological Hematologic Other
Weakness, fatigue, 
anorexia, failure to 
thrive, irritability,
Developmental delay 
and regression, 
paresthesia, hypotonia, 
hyporeflexia, seizures, 
ataxia, tremor, 
personality changes, 
depression
Megaloblastosis, anemia, 
pancytopenia
Glossitis, skin 
hyperpigmentation, 
vomiting, diarrhea, 
icterus
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cobalamin levels in the normal range, but unavailable for utilization in tissues (Rasmussen SA et al. 
2001). Both cobalamin and folate deficiency cause megaloblastic anemia with increased MCV, but 
only cobalamin deficiency causes neurological deficits.  
 Further diagnostic testing involves serum measurements of the metabolites methylmalonic acid 
and homocysteine, which accumulate in cobalamin deficiency (Schrier SL 2016). Homosysteine 
levels can also be elevated in folic acid, whereas elevated methylmalonic acid is specific for 
cobalamin deficiency (Rasmussen SA et al. 2001). Brain imaging may show atrophy and areas of 
delayed myelination (Stabler SP 2013).  
 When diagnosis of cobalamin deficiency is established, an investigation of the etiology should 
be initiated. A proper dietary history of both the mother and the child and testing for cobalamin 
deficiency in the mother can confirm nutritional cobalamin deficiency. The diagnosis of pernicious 
anaemia can be confirmed with the presence of antibodies to IF. Other parameters suggestive of 
pernicious anemia are elevated gastrin levels, low pepsinogen levels and a decrease in pepsinogen I 
to pepsinogen II ratio (Schrier SL 2016). 
3.3.4 Prevention and treatment  
 To augment prevention of cobalamin deficiency in infants, we need to increase awareness and 
educate pregnant women, especially vegan and vegetarian mothers, about the importance of 
cobalamin. These women may require supplementation during pregnancy and lactation (Oh RC, 
Brown DL 2003).  
 The treatment of cobalamin deficiency depends on the etiology. In mild asymptomatic 
deficiency diet modifications may be enough to bring serum cobalamin to normal levels. However 
pharmacological treatment is usually needed in most cases. Cobalamin is usually administered via 
the parenteral route either in the form of cyanocobalamin or hydroxocobalamin (Schrier SL 2016). 
As hydroxocobalamin has a longer half-life and thus requires less frequent dosing, it is 
Table 5. Interpretation of serum vitamin B12 levels 
Vitamin B12 level (pg/ml) Interpretation
>300  
200-300 
>200
Normal, deficiency unlikely  
Borderline, deficiency possible  
Low, consistent with deficiency
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recommended as the drug of choice by the WHO (Van Asselt DZB et al. 1998). Oral therapy is 
shown to be as effective, but many doctors are unaware of this and therefore choose the former. 
Treatment regimens vary but typically consists of an initial loading dose followed by a maintenance 
dose (Table 6). For patients with pernicious anaemia or other malabsorption conditions with 
permanent cobalamin deficiency, lifelong therapy is indicated (Oh RC, Brown DL 2003). 
 Long term prognosis depends on the severity and duration of cobalamin deficiency, thereof the 
need for early diagnosis and treatment (Rasmussen SA et al. 2001). Effective treatment should 
correct the anemia and improve neurological symptoms within 2 and 6 months, respectively. Many 
infants will have a full recovery, while some will unfortunately have persistent neurological damage 
(Stabler SP 2013). 
Table 6. Vitamin B12 treatment regimen 
Route of administration Initial dose (µg) Maintenance dose (µg)
Oral  
Intramuscular 
1000-2000/day for 1-2 weeks 
100-1000/day for 1-2 weeks 
1000/day 
100-1000/1-3 months 
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